INNATE PHARMA : announces first DSMB review of ongoing EffiKIR Phase II trial with lirilumab

INNATE PHARMA : announces first DSMB review of ongoing EffiKIR Phase II trial
with lirilumab

MARSEILLE, France, Sept. 17, 2013 (GLOBE NEWSWIRE) -- Innate Pharma SA (the
"Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company
developing first-in-class drugs for cancer and inflammatory diseases, today
announces that the Data and Safety Monitoring Board ("DSMB") completed its
first assessment of the EffiKIR study and unanimously recommended continuation
of the trial without modification.

The assessment was based on a safety analysis pre-planned for when the first
30 patients would be treated with a minimum of two cycles of therapy.

A DSMB is a committee of independent clinical research experts who review data
in ongoing clinical trials with particular attention to safety. DSMBs are
customarily established for large randomized multisite studies.

Hervé Brailly, CEO of Innate Pharma, said: "We are very pleased to see that
the EffiKIR trial is progressing on track, with this first DSMB review and
with more than a third of the patients already accrued".

About EffiKIR (study IPH2102-201):

EffiKIR is a double-blind placebo-controlled randomized Phase II trial of
lirilumab as maintenance treatment in elderly patients with Acute Myeloid
Leukemia ("AML") in first complete remission.

The protocol calls for inclusion of 150 patients, randomized into three arms.
Two arms will test single agent lirilumab at different doses and one arm will
receive placebo. The primary efficacy endpoint is leukemia-free survival.
Secondary endpoints include safety and overall survival.

The rationale of this trial is based on the capacity of activated Natural
Killer (NK) cells to directly kill tumor cells and trigger a broad immune
activation. This rationale is supported by clinical studies showing that
activated NK cells may significantly lower the recurrence of various
hematological malignancies, including AML, following hematopoietic stem cell

This trial is sponsored by Innate Pharma and performed in France, with the
participation of the two French clinical cooperative groups, ALFA and
GOELAMS^(1), harnessing the research effort of the French centers qualified to
treat patients with AML.

About lirilumab (IPH2102/BMS-986015):

Lirilumab is a fully human monoclonal antibody blocking interaction between
Killer-cell immunoglobulin-like receptors (KIR) on NK cells with their
ligands. Blocking these receptors facilitates activation of NK cells and,
potentially, destruction of tumor cells by the latter.

Lirilumab is licensed to Bristol-Myers Squibb Company (NYSE:BMY). As part of
the agreement between Innate Pharma and Bristol-Myers Squibb, Bristol-Myers
Squibb holds exclusive worldwide rights to develop, manufacture and
commercialize lirilumab and related compounds blocking KIR receptors, for all
indications. Under the agreement, Innate Pharma conducts the development of
lirilumab through Phase II in AML.

Lirilumab is currently tested in a randomized, double-blind,
placebo-controlled Phase II trial in elderly patients with AML in a
maintenance setting as well as in two combination Phase I trials in solid
tumors, respectively with ipilimumab and with the anti-PD-1 antibody nivolumab

About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approaches have led to licensing agreements with Novo
Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 84 employees as at June 30,

Learn more about Innate Pharma at

Practical Information about Innate Pharma shares:

ISIN code   FR0010331421
Ticker code IPH


This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to the
Risk Factors ("Facteurs de Risque") section of theDocument de
Referenceprospectus filed with the AMF, which is available on the AMF website
( or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                ATCG Press
Laure-Hélène Mercier        Marielle Bricman
Director, Investor Relations 
Phone: +33 (0)4 30 30 30 87  Mob.: +33 (0)6 26 94 18 53

[*]Ruggeri et al,Blood, 2007, Giebel et al.,Blood, 2003, Velardi et
al,Science, 2002

(1)ALFA: Acute Leukemia French Association. GOELAMS: Groupe Ouest-Est des
Leucémies Aiguës et Maladies du Sang(Acute Leukemia and Blood Diseases
West-Est Group)

DSMB Effikir English:
Press spacebar to pause and continue. Press esc to stop.